One-week losartan administration increases sodium excretion in cirrhotic patients with and without ascites

Yang, Ying-Ying; Lin, Han-Chieh; Lee, Wui-Chiang; Hou, Ming-Chih; Lee, Fa-Yauh; Chang, Full-Young; Lee, Shou-Dong
March 2002
Journal of Gastroenterology;2002, Vol. 37 Issue 3, p194
Academic Journal
Background. Losartan, a highly selective angiotensin II type 1 receptor antagonist, has been reported to have a significant portal hypotensive effect in cirrhotic patients. A recent study also showed that losartan exerted a dramatic natriuretic effect in preascitic cirrhosis. The influence of losartan on renal hemodynamics and sodium homeostasis in cirrhotic patients with ascites is unclear. This study was undertaken to evaluate the renal effects of 1-week losartan treatment in cirrhotic patients with and without ascites. Methods. All 12 patients in the study received a daily oral dose of 25 mg losartan for 7 consecutive days. Effective renal plasma flow, urine volume, creatinine clearance, 24h urine sodium excretion and fractional excretion of sodium, blood urea nitrogen, and serum creatinine were measured before and after treatment. Results. In cirrhotic patients without ascites, creatinine clearance, 24-h urinary sodium excretion, and fractional excretion of sodium were significantly increased after losartan administration. Effective renal plasma flow and serum creatinine showed almost no change after treatment. In cirrhotic patients with ascites, creatinine clearance, 24-h urinary sodium excretion, fractional excretion of sodium, and effective renal plasma flow were significantly increased after losartan administration. In addition, the magnitudes of the increases in the fractional excretion of sodium and in the 24-h urinary sodium excretion were greater in cirrhotic patients with ascites than in those without ascites. Conclusions. One-week treatment with losartan increases sodium excretion in association with an improvement of renal function in cirrhotic patients with and without ascites. The natriuretic effect was more profound in cirrhotic patients with ascites than in those without ascites.


Related Articles

  • Clinical Implications of the Serum Apelin Level on Portal Hypertension and Prognosis of Liver Cirrhosis. Yoo Li Lim; Eunhee Choi; Yoon Ok Jang; Youn Zoo Cho; Yong Seok Kang; Soon Koo Baik; Sang Ok Kwon; Moon Young Kim // Gut & Liver;Jan2016, Vol. 10 Issue 1, p109 

    Background/Aims: Levels of serum apelin (s-apelin), an endogenous ligand for angiotensin-like receptor 1, have been shown to be related to hepatic fibrosis and hemodynamic abnormalities in preclinical studies. We investigated the clinical implications of s-apelin as a noninvasive prognostic...

  • Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects. Fricker, Anne F.; Nussberger, Jürg; Meilenbrock, Susanne; Brunner, Hans R.; Burnier, Michel // Kidney International;Dec1998, Vol. 54 Issue 6, p2089 

    Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects. Background. Non-steroidal anti-inflammatory drugs are known to promote sodium retention and to blunt the blood pressure lowering effects of several classes of antihypertensive agents including...

  • Angiotensin II--mediated expression of p27 [sup Kip1] and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Hannken, Tete; Schroeder, Regine; Stahl, Rolf A.K.; Wolf, Gunter // Kidney International;Dec1998, Vol. 54 Issue 6, p1923 

    Discusses a study on whether angiotensin II stimulate superoxide anions formation in cells. Factors that lead to tubular hypertrophy; Relationship between oxygen and cell cycle regulation; Role of oxygen in growth.

  • Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension. Billecke, Scott S.; Marcovitz, Pamela A. // Vascular Health & Risk Management;2013, Vol. 9, p95 

    The use of multiple drug regimens is increasingly recognized as a tacit requirement for the management of hypertension, a necessity fueled in part by rising rates of metabolic syndrome and diabetes. By targeting complementary pathways, combinations of antihypertensive drugs can be applied to...

  • Effects of long-term losartan and l-arginine treatment on haemodynamics, glomerular filtration, and SOD activity in spontaneously hypertensive rats. Miloradovik, Zoran; Jovovik, nurðica; Mihailovik-Stanojevik, Nevena; Milanovik, Jelica Grujik; Milanovik, Slaðan // Canadian Journal of Physiology & Pharmacology;Apr2008, Vol. 86 Issue 4, p210 

    Recently, it has been reported that losartan, an angiotensin II receptor (ATR) antagonist, depresses the angiotensin II-induced production of superoxide radicals. Also, in spontaneously hypertensive rats (SHR) endothelial dysfunction is associated with decreased nitric oxide (NO) synthesis. In...

  • Effect of Candesartan on Microalbuminuria and Albumin Excretion Rate in Diabetes. Bilous, Rudy; Chaturvedi, Nish; Sjølie, Anne Katrin; Fuller, John; Klein, Ronald; Orchard, Trevor; Porta, Massimo; Parving, Hans-Henrik // Annals of Internal Medicine;7/7/2009, Vol. 151 Issue 1, p11 

    Background: Microalbuminuria in diabetes is strongly predictive of nephropathy, end-stage renal disease, and premature cardiovascular morbidity and mortality. Effective preventive therapies are therefore a clinical priority. Objective: To determine whether the angiotensin-receptor blocker...

  • Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Carlini, Raul G.; Dusso, Adriana S.; Obialo, Chamberlain I.; Alvarez, Ulises M.; Rothstein, Marcos // Kidney International;May1993, Vol. 43 Issue 5, p1010 

    Hypertension is a major complication of rHuEPO therapy in hemodialysis (HD) patients. We have previously reported that patients receiving rHuEPO intravenously (i.v.) had higher mean arterial pressure (MAP) and plasma endothelin-1 (ET-1) levels than those in which the hormone was administered...

  • Expression and clinical significance of angiotensin II type 1 receptor in human hepatocellular carcinoma. YUN-FEI DUAN; XIAO-DONG LI; FENG ZHU; FENG ZHANG // Experimental & Therapeutic Medicine;2014, Vol. 7 Issue 2, p323 

    This study aimed to investigate the expression of angiotensinII type1 receptor (AT-1R) mRNA and the AT-1R protein in human primary hepatocellular carcinoma (PHC), and to attempt to elucidate their association with pathological and clinical characteristics. Fresh tumor and normal liver tissues...

  • Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers. BURNIER, MICHEL; BUCLIN, THIERRY; BIOLLAZ, JÉRÔME; NUSSBERGER, JURG; WAEBER, BERNARD; BRUNNER, HANS R. // Kidney International Supplement;Jun1996, Issue 55, pS-24 

    The article discusses the pharmacokinetic and pharmacodynamic properties of three angiotensin II receptor antagonists. Both the mother compound and the metabolite of losartan are active receptor antagonists. TCV 116, an ester pro-drug, and irbesartan, an antagonists that does not require active...

  • Preclinical pharmacology of saralasin. Castellion, Alan W.; Fulton, Robert W. // Kidney International Supplement;Mar1979, Issue 9, p11 

    Saralasin is a highly soluble and stable All antagonist with a relatively short half-life; therefore, its effects are rapidly reversible when administered i.v. Acute and subacute studies have shown only transient toxicosis with no significant pathology or teratology, Saralasin's angiotensin...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics